Dear Editor,

We would like to thank you for all of the work carried out by BMJ and the reviewers, who all spent a great deal of time improving our manuscript. We appreciate your practical proposals and would now like to submit a revised version of the article previously submitted (Prolonged exposure to high doses of cyproterone acetate and risk of meningioma in women: French cohort study on 253,777 exposed women). Please find below the point-by-point response to the questions raised by the BMJ and the reviewers.

Since the initial submission, an 8-minute e-congress oral presentation in French, with an abstract only available in French, was published in March 2020.


We would like to apologise for our late reply and we thank you for the additional time that you granted us as a result of our temporary difficulties.

Confinement and technical difficulties accessing very secure data. An important member of our team was sick and hospitalized for COVID-19 and the epidemiologists had a large workload with several studies and governmental reports devoted to COVID-19.

I confirm that Professor Sébastien Froelich has been one of the main authors (penultimate) of this work from the beginning. I sent during the initial submission in January 2020 his declaration of interest and his name is clearly indicated on all documents (main document ...). See pdf initial submission dated January 24, 2020. By mistake I had not indicated in step 5 of the electronic submission what is now done. I apologize for that.

We hope that the revised article will be of interest to your extensive readership, and will be useful for women taking cyproterone acetate and for prescribing physicians.

On behalf of all authors
Best regards,
Dr Alain Weill